SCHEMBL17439490

SCHEMBL17439490

Cc1ccc(F)c(OBOc2cc(C)ccc2F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.41
HTR1A P08908 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
NFE2L2 Q16236 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2A6 P11509 2/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RAB9A P51151 2/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1174545 0.87 ACHE (0.41) ACHEHTR1ASLC6A2SLC6A4NFE2L2
SCHEMBL333943 0.77 CA3 (0.41) NFE2L2CA9ALDH1A1
SCHEMBL12321 0.77 ACHE (0.62) ACHEHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL594053 0.77 ACHE (0.44) ACHECA1CA2CA9CYP1A2
SCHEMBL13180059 0.76 CA1 (0.44) ACHEHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL2281581 0.76 PPARG (0.38) SLC6A2SLC6A4SLC6A3MRGPRX4
SCHEMBL1286402 0.75 CA12 (0.48) NFE2L2CA1CA2CA9CYP1A2
SCHEMBL4474308 0.74 MAPT (0.49) ACHESLC6A4CA1CA2CA9
SCHEMBL7233333 0.74 TRPA1 (0.50) ACHESLC6A2CA1CA2CA9
SCHEMBL188251 0.74 ACHE (0.71) ACHECA1CA2CA9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10391099-B2 Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines GRUENENTHAL GMBH (DE) 2019-08-27 US disclosed
EP-3415510-A1 NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS Grünenthal GmbH (DE) 2018-12-19 EP disclosed
US-20170065603-A1 Novel 2,5-substituted pyrimidines GRUENENTHAL GMBH (DE) 2017-03-09 US disclosed
US-9546158-B2 2,5-substituted pyrimidines GRUENENTHAL GMBH (DE) 2017-01-17 US disclosed
US-20160016938-A1 Novel 2,5-substituted pyrimidines GRUENENTHAL GMBH (DE) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170065603-A1 Novel 2,5-substituted pyrimidines PDE4B, PDE4A, PDE12 ACHE 347/4885HTR1A 1377/4885SLC6A2 1747/4885
US-20160016938-A1 Novel 2,5-substituted pyrimidines PDE4B, PDE4A, PDE12 ACHE 347/4885HTR1A 1377/4885SLC6A2 1747/4885
US-10391099-B2 Method of treating psoriatic arthritis, psoriasis, and chronic obstructive pulmonary disease with a novel 2,5-substituted pyrimidines PDE4B, PDE4A, PDE12 ACHE 1646/4885HTR1A 3352/4885SLC6A2 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.